
The United States Food and Drug Administration proposed revoking approval for Salerno Pharmaceuticals' liquid cholesterol medication on Tuesday afternoon. The regulatory action targets the drug FloLipid over missing mandatory disclosures.
The US Food and Drug Administration is proposing to withdraw approval for Salerno Pharmaceuticals liquid cholesterol drug FloLipid. The agency states the company repeatedly failed to file required annual reports.

The United States Food and Drug Administration proposed revoking approval for Salerno Pharmaceuticals' liquid cholesterol medication on Tuesday afternoon. The regulatory action targets the drug FloLipid over missing mandatory disclosures.
Everything you use on the web — faster, and in your pocket.